CancerVax Universal Cancer Platform Demonstrates Liver-Sparing Properties in Preclinical Studies
Key Insights
CancerVax (search) announced that recent in-vitro studies confirmed its universal cancer (search) treatment platform significantly reduces liver toxicity, addressing a major failure point for many cancer therapies.
The company's AI-designed nanoparticle platform uses a dual-targeting mechanism with Smart mRNA (search) payloads that are dramatically deactivated in healthy human liver cells while remaining active against pancreatic and liver cancers.
The platform aims to create off-the-shelf injections for multiple cancer (search) types using universal biomarkers, potentially treating patients across 200 cancer types rather than requiring individualized therapies for 8 billion people.
CancerVax (search), Inc. announced that recent in-vitro studies have validated its universal cancer (search) treatment platform's ability to significantly reduce liver toxicity, addressing one of the most common causes of clinical trial failures in oncology drug development. The preclinical biotech company reported that its Smart mRNA (search) technology was dramatically deactivated in healthy human liver cells while maintaining activity against target cancer cells.
Addressing a Critical Challenge in Cancer Drug Development
Liver toxicity represents a major obstacle in cancer (search) therapeutics, as the liver serves as the primary site for drug metabolism. According to CancerVax (search), many cancer therapies fail in clinical trials because a significant portion of administered drugs accumulate in the liver, causing liver damage or failure. This problem affects nearly all cancer drug classes, including chemotherapy, antibody-drug conjugates, CAR-T therapies, and PD-1 (search)/PD-L1 (search) checkpoint inhibitors.
To overcome this challenge, CancerVax (search)'s science team leveraged artificial intelligence and machine-learning techniques to design technology that specifically avoids healthy tissues and organs, particularly the liver.
Dual-Targeting Mechanism Shows Precision
The CancerVax (search) platform employs nanoparticles (search) with a two-step cell-targeting mechanism designed to harness the body's existing immunity. In the detection phase, nanoparticles first bind to surface proteins highly associated with target cancer (search) cells, designated as "Marker1 (search)." During the activation phase, once inside cancer cells, the nanoparticles release proprietary Smart mRNA (search) payloads that activate only in the presence of cancer-specific genetic signatures called "Marker2 (search)."
These Smart mRNAs instruct cancer (search) cells to produce proteins associated with well-immunized diseases like measles, effectively tricking the immune system into killing cancer cells as if they were common diseases.
Promising Results in Human Liver Cell Studies
In the recent in-vitro studies, CancerVax (search) confirmed that its Smart mRNAs designed for pancreatic and liver cancers were dramatically deactivated in healthy human liver cells. This represents a significant advancement from previous experiments that used artificial non-cancerous cell models such as HEK293.
"These results are striking," said Dr. George Katibah, Chief Scientific Officer. "This is the first time we're using human-derived healthy liver cells, and the results were incredibly exciting and rewarding to see. This gives us confidence that our targeted therapy will reduce potential harm to the liver and other major organs."
Universal Approach Aims to Reduce Treatment Costs
The platform's universal design could potentially transform cancer (search) treatment economics. Dr. Adam Grant, Principal Scientist, explained that the company's proprietary AI algorithms mine cancer genomics databases to identify universal biomarkers for both Marker1 (search) and Marker2 (search) combinations.
"As a result, accessible off-the-shelf injections can be easily developed for multiple cancer (search) types, instead of expensive custom therapies for individual patients," Grant noted. "We believe some Marker1 (search) and Marker2 (search) combinations can be used for multiple cancer indications as well. In other words, a single version of our injection has the potential to treat patients across multiple cancer types."
This approach could dramatically reduce drug costs, as Grant pointed out there are approximately 200 cancer (search) types compared to 8 billion individual people worldwide.
Platform Technology and Development Status
CancerVax (search) describes its approach as designed to detect, mark, and kill only cancer (search) cells by making them appear like well-immunized common diseases such as measles or chickenpox to the body's natural immune system. The company envisions a future where treating cancer could be as simple as receiving an injection.
The company remains in the preclinical stage of development, with the universal cancer (search) treatment platform designed to be customizable as an injection for treating multiple cancer types.